Biogen Inc. (BIIB)

Market Cap	20.50B
Revenue (ttm)	9.68B
Net Income (ttm)	1.63B
Shares Out	146.37M
EPS (ttm)	11.18
PE Ratio	12.54
Forward PE	8.85
Dividend	n/a
Ex-Dividend Date	n/a

Volume	564,835
Open	142.35
Previous Close	141.60
Day's Range	139.86 - 142.35
52-Week Range	128.51 - 238.00
Beta	0.01
Analysts	Buy
Price Target	220.50 (+57.46%)
Earnings Date	Apr 23, 2025

About BIIB

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: Sep 16, 1991
• Employees: 7,605
• Stock Exchange: NASDAQ
• Ticker Symbol: BIIB
• Website: https://www.biogen.com

Financial Performance

In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.

Analyst Forecast

According to 27 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price forecast is $220.5, which is an increase of 57.46% from the latest price.

Price Target

$220.5

(57.46% upside)

Analyst Consensus: Buy